EUVIMEDEUVIMED entdecken
Crossref

Real-World Evaluation of Treatment Patterns and Clinical Outcomes among Patients With Chronic Myeloid Leukemia in Chronic Phase Treated With Asciminib in Clinical Practice in the United States

Ehab L Atallah, David Wei, Dominick Latremouille-Viau, Carmine Rossi, Andrea Damon, Germano Ferreira, Annie Guérin, Kejal Jadhav

Clinical Lymphoma Myeloma and Leukemia · 2025

DOI: 10.1016/j.clml.2024.09.013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Ehab L Atallah und 7 weiteren Autor:innen. Beteiligte Einrichtung: Medical College of Wisconsin, Milwaukee, WI. Electronic address: eatallah@mcw.edu. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Pyrazoles, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Novartis Pharmaceuticals Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsPyrazolesLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, Myeloid, Chronic-PhaseHumansFemaleMaleMiddle AgedAgedUnited StatesTreatment OutcomeAdultFusion Proteins, bcr-ablAged, 80 and overNiacinamide

Stichwörter der Autor:innen

Hematological malignanciesMolecular responsePrognosisReal-worldTyrosine kinase inhibitors

Substanzen

asciminibProtein Kinase InhibitorsPyrazolesFusion Proteins, bcr-ablNiacinamide

Autor:innen und Institutionen

  • Medical College of Wisconsin, Milwaukee, WI. Electronic address: eatallah@mcw.edu.
  • Novartis Pharmaceuticals Corporation, East Hanover, NJ.
  • Analysis Group, Inc, Montréal, Canada.
  • Novartis Pharma AG, Basel, Switzerland.

Förderung

  • Novartis Pharmaceuticals Corporation

Zitieren

APA

Atallah, E. L., Wei, D., Latremouille-Viau, D., Rossi, C., Damon, A., Ferreira, G., Guérin, A., & Jadhav, K. (2025). Real-World Evaluation of Treatment Patterns and Clinical Outcomes among Patients With Chronic Myeloid Leukemia in Chronic Phase Treated With Asciminib in Clinical Practice in the United States. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2024.09.013

Vancouver

Atallah EL, Wei D, Latremouille-Viau D, Rossi C, Damon A, Ferreira G, et al. Real-World Evaluation of Treatment Patterns and Clinical Outcomes among Patients With Chronic Myeloid Leukemia in Chronic Phase Treated With Asciminib in Clinical Practice in the United States. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2024.09.013

BibTeX
@article{Atallah2025,
  author = {Atallah, Ehab L and Wei, David and Latremouille-Viau, Dominick and Rossi, Carmine and Damon, Andrea and Ferreira, Germano and Guérin, Annie and Jadhav, Kejal},
  title = {Real-World Evaluation of Treatment Patterns and Clinical Outcomes among Patients With Chronic Myeloid Leukemia in Chronic Phase Treated With Asciminib in Clinical Practice in the United States},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2025},
  doi = {10.1016/j.clml.2024.09.013}
}
Kostenlos starten →